Balaxi Pharmaceuticals Ltd vs Neuland Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Balaxi Pharmaceuticals Ltd is ₹ 26.63 as of 30 Apr 15:30 . The P/E Ratio of Balaxi Pharmaceuticals Ltd changed from 13.8 on March 2021 to 14.1 on March 2025 . This represents a CAGR of 0.43% over 5 yearsThe P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 59.9 on March 2025 . This represents a CAGR of 12.39% over 5 years The Market Cap of Balaxi Pharmaceuticals Ltd changed from ₹ 524.5 crore on March 2021 to ₹ 352.89 crore on March 2025 . This represents a CAGR of -7.62% over 5 yearsThe Market Cap of Neuland Laboratories Ltd changed from ₹ 2678 crore on March 2021 to ₹ 15494 crore on March 2025 . This represents a CAGR of 42.05% over 5 years The revenue of Balaxi Pharmaceuticals Ltd for the Dec '25 is ₹ 72.64 crore as compare to the Sep '25 revenue of ₹ 57.76 crore. This represent the growth of 25.76% The revenue of Neuland Laboratories Ltd for the Dec '25 is ₹ 447.76 crore as compare to the Sep '25 revenue of ₹ 516.07 crore. This represent the decline of -13.24% The ebitda of Balaxi Pharmaceuticals Ltd for the Dec '25 is ₹ 3.19 crore as compare to the Sep '25 ebitda of ₹ 2.75 crore. This represent the growth of 16% The ebitda of Neuland Laboratories Ltd for the Dec '25 is ₹ 85.19 crore as compare to the Sep '25 ebitda of ₹ 157.35 crore. This represent the decline of -45.86% The net profit of Balaxi Pharmaceuticals Ltd changed from ₹ 6.48 crore to ₹ 0.31 crore over 7 quarters. This represents a CAGR of -82.40% The net profit of Neuland Laboratories Ltd changed from ₹ 97.87 crore to ₹ 40.57 crore over 7 quarters. This represents a CAGR of -39.54% The Dividend Payout of Balaxi Pharmaceuticals Ltd changed from 3.41 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Neuland Laboratories Ltd changed from 8.03 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of -5.76% over 5 years .

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited was initially incorporated in the name of 'The Anandam Rubber Company Limited' on September 28, 1942.
The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' on August 08, 2017 and further changed to Balaxi Pharmaceuticals Limited in 2021.
Initially, the Company was incorporated with the object of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading.
The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
Neuland Drugs & Pharmaceuticals Pvt.
Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

FAQs for the comparison of Balaxi Pharmaceuticals Ltd and Neuland Laboratories Ltd

Which company has a larger market capitalization, Balaxi Pharmaceuticals Ltd or Neuland Laboratories Ltd?

Market cap of Balaxi Pharmaceuticals Ltd is 147 Cr while Market cap of Neuland Laboratories Ltd is 19,243 Cr

What are the key factors driving the stock performance of Balaxi Pharmaceuticals Ltd and Neuland Laboratories Ltd?

The stock performance of Balaxi Pharmaceuticals Ltd and Neuland Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Balaxi Pharmaceuticals Ltd and Neuland Laboratories Ltd?

As of May 4, 2026, the Balaxi Pharmaceuticals Ltd stock price is INR ₹26.63. On the other hand, Neuland Laboratories Ltd stock price is INR ₹14998.7.

How do dividend payouts of Balaxi Pharmaceuticals Ltd and Neuland Laboratories Ltd compare?

To compare the dividend payouts of Balaxi Pharmaceuticals Ltd and Neuland Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.